US2008226669A1PendingUtilityA1
Multivalent pcv2 immunogenic compositions and methods of producing such compositions
Assignee: BOEHRINGER INGELHEIM VETMEDPriority: Dec 29, 2005Filed: Dec 28, 2006Published: Sep 18, 2008
Est. expiryDec 29, 2025(expired)· nominal 20-yr term from priority
A61P 31/20A61P 31/22A61P 31/12A61P 31/04A61P 37/00A61P 37/04A61P 31/14A61K 38/00A61K 39/12C12N 2750/10034C12N 2770/10034A61K 2039/545A61K 39/04A61K 2039/55566C12N 2750/14043A61K 2039/70A61K 2039/552A61K 49/0004C07K 14/005A61K 39/295
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine,
Claims
exact text as granted — not AI-modified1 . A multivalent combination vaccine, comprising an immunological agent effective for reducing the incidence of or lessening the severity of porcine circovirus type 2 infections and at least one immunogenic active component effective against another disease-causing organism in swine.
2 . The multivalent combination vaccine of claim 1 , wherein said immunological agent effective for reducing the incidence of or lessening the severity of porcine circovirus type 2 infection is a porcine circovirus type 2 antigen.
3 . The multivalent combination vaccine of claim 2 , wherein the porcine circovirus type 2 antigen is inactivated porcine circovirus type 2 antigen, a live modified or attenuated porcine circovirus type 2, a chimeric virus that comprises at least an immunogenic amino acid sequence of porcine circovirus type 2, or any other polypeptide or component that comprises at least an immunogenic amino acid sequence of porcine circovirus type 2.
4 . The multivalent combination vaccine of claim 2 , wherein said porcine circovirus type 2 antigen is a protein encoded by a DNA sequence having at least 80% sequence identity with ORF2 of a porcine circovirus type 2.
5 . The multivalent combination vaccine of claim 2 , wherein said porcine circovirus type 2 antigen is baculovirus expressed ORF2 antigen.
6 . The multivalent combination vaccine of claim 1 , wherein said immunogenic active component effective against another disease-causing organism in swine is selected from the group consisting of an antigen of: Actinobacillus pleuropneumonia ; Adenovirus; Alphavirus such as Eastern equine encephalomyelitis viruses; Bordetella bronchiseptica; Brachyspira spp., preferably B. hyodyentheria; B. piosicoli, Brucella suis , preferably biovars 1, 2, and 3: Clasical swine fever virus; Clostridium spp., preferably Cl. difficile, Cl. perfringens types A, B, and C, Cl. novyi, Cl. septicum, Cl. tetani ; Coronavirus, preferably Porcine Respiratory Corona virus; Eperythrozoonosis suis; Erysipelothrix rhsiopathiae; Escherichia coli; Haemophilus parasuis , preferably subtypes 1, 7 and 14; Hemagglutinating encephalomyelitis virus; Japanese Encephalitis Virus; Lawsonia intracellularis; Leptospira spp., preferably Leptospira australis; Leptospira canicola; Leptospira grippotyphosa; Leptospira icterohaemorrhagicae ; and Leptospira interrogans; Leptospira pomona; Leptospira tarassovi; Mycobacterium spp., preferably M. avium, M. intracellulare and M. bovis; Mycoplasma hyopneumoniae ( M hyo ); Pasteurella multocida ; Porcine cytomegalovirus; Porcine Parvovirus; Porcine Reproductive and Respiratory Syndrome (PRRS) Virus, Pseudorabies virus; Rotavirus; Salmonella spp., preferably S. thyhimurium and S. choleraesuis; Staph. hyicus; Staphylococcus spp., preferably Streptococcus spp., preferably Strep. suis ; Swine herpes virus; Swine Influenza Virus; Swine pox virus; Swine pox virus. Vesicular stomatitis virus; Virus of vesicular exanthema of swine, and combinations thereof.
7 . The multivalent combination vaccine of claim 1 , wherein said immunogenic active component effective against another disease-causing organism in swine is selected from the group consisting of any antigen contained in Enterisol® Ileitis, Enterisol® Ileitis FF, Enterisol® SC-54, Enterisol® SC-54 FF, Enterisol® ERY-ALC, Ingelvac® APP ALC, Ingelvac® AR4, Ingelvac® HP-1, Ingelvac® HPE-1, Ingelvac® M. hyo , Ingelvac® PRRS MLV, Ingelvac® PRRS ATP, Ingelvac® PRV-G1, Reprocyc® PRRS PLE, Reprocyc® PLE, Tetguard™, Toxivac® AD+E, Toxivac® Plus Parsius, (all of Boehringer Ingelheim, St. Joseph, Mo., USA); Circovent, Porcilis Coli, Porcilis ERY+ PARVO, Porcilis Ery, Porcilis Glasser, Porcilis Parvo, Porcilis Porcoli DF, Porcilis APP, Porcilis AR-T, Porcilis AR-T DF, Porcilis Porcoli, Porcilis Porcoli Diluvac forte, Porcilis PRRS, Porcilis Porcol 5, Porcilis Aujeszky, Porcilis Begonia Diluvac, Porcilis Begonia I.D.A.L., Porcilis Begonia Unisole, Porcilis M two, Porcilis Atrinord, Myco Silencer® BPM, Myco Silencer® BPME, Myco Silencer® ME, Myco Silencer® M, Myco Silencer® Once, Myco Silencer® MEH, Rhiniogen® BPE, Rhiniogen® CTE 5000, Rhinogen® CTSE, Score, Sow Bac® E II, Sow Bac® CE II, Sow Bac® TREC, ProSystem® CE, ProSystem® RCE, ProSystem® TREC, ProSystem® Pillmune, ProSystem®Rotamune® with Imugan® II, ProSystem® Rota, ProSystem® Rotamune KV, ProSystem® TG-Emune® Rota with Imugan® II, ProSystem® TGE/Rota, ProSystem® TG-Emune® with Imugen®. ProSystem® TGE, MaGESTIC 7, MaGESTIC 8, MaGESTic™ with Spurt-1, MaGESTic® 7 with Spur®, MaGESTic® 8 with Spur®, End-FLUence® with Imugen® II, End-FLUence® 2, PRRomiSE®, PRV-Begonia with Diluvac Forte®, Argus® SC/ST. Strep Bac, Strep Bac® with Imugen® II, Colisorb, Heptavac, Lambivac, Porcovac plus, Erysorb Parvo all of Intervet Inc., Millsboro, Del., USA); Hyoresp, Circovac, Neocolipor, Parvoruvac, Parvosuin, Progresses, Viraflu, Akipor 6.3, Jespur gl-, Jesflu gl- (all of Merial LTD, Duluth. GA); ER BAC® PLUS, ER BAC®, ER BAC® PLUS/LEPTOFERM-5® ER BAC® Leptoferm-5®, Farrowsure®, Farrowsure® B, FARROWSURE® PLUS B, FARROWSURE® PLUS, FARROWSURE® PRV, FARROWSURE B-PRV, FLUSURE™, FLUSURE™ RTU, FLUSURE™/ER BAC® PLUS, FLUSURE™/ER BAC PLus®, FLUSURE™/RESPISURE®, FLUSURE™/RESPISURE® RTU, FLUSURE™/RESPISURE-ONE®/ER BAC® PLUS, FLUSURE™/RespiSure 1 ONE®/ER BAC Plus®, FLUSURE™/RESPISURE ONE®, FLUSURE□/RESPISURE 1 ONE®, FLUSURE/Farrowsure Plus, FLUSURE/Farrowsure Plus B, LITTERGUARD® LT-C, LITTERGUARD® LT, PleuroGuard® 4, Pneumosuis III, Stellamune One, Stellamune Uno, Stellamune Once, Stellamune Mono, Stellamune Mycoplasma, Respisure One, Respisure®, Respisure 1 ONE®, Respisure 1 One®/ER Bac Plus®, Enduracell T, Zylexis (formerly known as Baypamune), Atrobac® 3, BratiVac®, BratiVac®-B, Leptoferm- Parvo Vac®/Leptoferm-5®, PR-Vac®-Killed, PR-Vac®, PR-Vac Plus™. (all of Pfizer Inc., New York, N.Y., USA); Suvaxyn MH One, Suvaxyn RespiFend® MR Suvaxyn Mycoplasma, Suvaxyn Aujeszky Bartha+Diluent, Suvaxyn Aujeszky Bartha+o/w, Suvaxyn Aujeszky-Flu, Suvaxyn Aujeszky 783+o/w, Suvaxyn Ery, Suvaxyn Flu, Suvaxyn M.hyo. Suvaxyn MH-One, Suvaxyn Parvo ST, Suvaxyn Parvo/E, Suvaxyn RespiFend® APP, Suvaxyn RespiFend® HPS, Suvaxyn RespiFend® MH/HPS, Suvaxyn RespiFend® MH. Suvaxyn® AR/T/E, Suvaxyn® EC-4, Suvaxyn® E, Suvaxyn®-E, Suvaxyn® E-oral, Suvaxyn® PLE, Suvaxyn® PLE/PrV gpl-, Suvaxyn® LE+B, Suvaxyn® PLE+B, Suvaxyn® PLE+B/PrV gpl-, Suvaxyn® SIV, Suvaxyn® SIV/Mh-one, Suvaxyn® P, Suvaxyn® PrV gpl-, Suvaxyn® PCV-2 One Shot (all of Fort Dodge Animal Health, Overland Park, Kans. USA (Wyeth); SCOURMUNE®. SCOURMUNE®-C, SCOURMUNE®-CR, AR-PAC®-PD+ER, AR-PARAPAC®+ER, M+ Rhusigen®, M+PAC®, MaxiVac Excell®3, MaxiVac®H1N1 MaxiVac® H3N2, MaxiVac®-FLU, MaxiVac®-M+, MaxiVac Excell®, MaxiVac Excell 3, PARAPAC®, PNEU PAC®, PNEU PAC®-ER, PNEU PAC®+ER, PRV/Marker Gold® PRV/Marker Gold®, PRV/Marker Gold®-MaxiVac® FLU, Rhusigen™, Gletvax 6, Covexin 8, M+PAC, Gletvax plus, M-Parapac™ SS PAC® (all of Schering-Plough Animal Health Corporation, Kenilworth, N3, USA): AMERVAC-PRRS, AUSKIPRA-BK, AUSKIPRA-GN, COLISUIN-CL, COLISUIN-TP, ERYSIPRAVAC, GRIPORK, HIPRASUIS-GLÄSSER, MYPRAVAC SUIS, NEUMOSUIR PARVOSUIN, PARVOSUIN-MR, PARVOSUIN-MR/AD, RINIPRAVAC-DT, SUIPRAVAC-PRRS, SUIPRAVAC-RC, TOXIPRA PLUS (all of Laboratories Hipra S.A., Amer, Girona, Spain); Clostricol, Coliporc Plus. Haeppovac, Per-C-Pore, Porciparvac, RESPIPORC ART+EP, RESPIPORC FLU, Respiporc M. HYO 1 SHOT, Rhusiovac, Rotlauf-Lebendimpfstoff, Salmoporc. Suisaloral, AK-vac MK35 (all of IDT Impfstoffwerk DessaTornau, Tornau, Germany); Mypravac Suis, (Albrecht GmbH, Germany); Haemo Shield® P. Parapleuro Shield® P, Parapleuro Shield® P+BE, Rhinicell® FD, Rhini Shield™TX4, Prefarrow Shield® 9, Prefarrow Strep Shield®, Clostratox®BCD, Clostratox® C, Clostratox® Ultra C 1300, Porcine Ecolizer® 3+C, Porcine Pili Shield™+C, Porcine Pili Shield™ Porcine Ecolizer® 3, Ery Serum™Ery Shield™Ery Vac Oral, Ery Shield™+L5, PanSTAR™Ery, Erycell™Parvo Shield®E, Parvo Shield® L5E, Parvo Shield® L5, Parvo Shield®, Para Shield®, PneumoSTAR SPY, PneumoSTAR™ Myco. Lepto Shield™5, Myco Shield™Salmo Shield® 2, Salmo Shield® Live, Amitox Tet™C. Perfingens Type A Toxoid (all of Novartis Animal Health, Basel, Switzerland); Nitro-Sal (Akro); or combinations thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.